schizophrenia
Conditions
Interventions
Experimental group:antipsychotics (Risperidone/Paliperidone/Olanzapine) and Sevoflurane
Control group:antipsychotics (Risperidone/Paliperidone/Olanzapine)
Sponsors
Guangzhou Women and Children's Medical Center
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Subjects meeting with the DSM-5 criteria for diagnose of schizophrenia, the course of disease within 5 years; 2. Male or female, aged 18-50 years; 3. Subjects who are hospitalized (in-hospital patients) at screening phase, and can remain in hospital during study perious; 4. Subjects who are in the phrase of acute schizophrenia with a score from 70 to 120 on the PANSS scale and are appropriate to receive sevoflurane inhalation according to the investigators judgment; 5. Subjects with a minimum score of 14 on the PANSS -excited component (PANSS-EC) and at least 1 item no less than 4 (P4. excited, P7. Hostility, G4. Physical tension, G8. Uncooperative, G14. Impulse control disorder); 6.No long-term antipsychotic injection within 6 months; 7. An informed consent with the subject's signature (or legally acceptable representative) and the date of signature indicating that the subject (or a legally acceptable representative) has been informed of all information relating to the study and are willing to participate in the study; 8. No systemic antipsychotics use in 2 weeks prior to enrollment.
Exclusion criteria
Exclusion criteria: 1. Acute phrase due to delirium, seizures, affective psychosis, poisoning, or substance abuse withdrawal reactions; 2. Relevent history or current presence of any major or unstable cardiovascular, respiratory, neurological, renal, hepatic, endocrine, immunologic or other systemic disease; 3. Confirmed clinically significant abnormal laboratory values; 4. Clinically significant ECG abnormality; 5. Subjects with a history of QTc prolongation or QTc of 450 msec or greater before drug adiministration; 6. Subjects with serum K+ or Mg2+ beyond the normal range; 7. A history of malignant syndrome or tardive dyskinesia history; 8. Pregnant or lactating women; 9. Monoamine oxidase antidepressants were administered prior to the study in 2 weeks; 10. Long-acting antipsychotics were administered prior to screening in 6 months; 11. Participation in other studies within the last 30 days before the current study begins and /or during study participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PANSS; | — |
Secondary
| Measure | Time frame |
|---|---|
| BPRS;TESS;MCCB;CGI-I;CGI-S;AMS;PANSS-EC;PSP;AEs;MAC;weight;hemodynamic parameters; | — |
Countries
China
Contacts
Public ContactXingrong Song
Guangzhou Women and Children's Medical Center
Outcome results
None listed